Indy Standard

U.S. Senator Todd Young from Indiana has joined a bipartisan coalition of 55 senators in urging Senate leadership to reauthorize the Special Diabetes Program (SDP). The program's current funding, which was increased for the first time in two decades earlier this year, is set to expire on December 31, 2024.

In a letter addressed to Senate leaders, the senators highlighted the significant human and economic impact of diabetes in the United States. They stated: “Diabetes is one of our country’s most costly diseases in both human and economic terms, affecting people of all ages and races, and in every region of our country.” The letter also pointed out that diabetes accounts for substantial healthcare spending, including one-third of Medicare dollars.

The Special Diabetes Program has been active for 27 years and provides essential resources and research advancements for millions of Americans affected by diabetes. The senators emphasized its importance: “It is essential that we continue to invest in the research necessary to develop a cure for diabetes.”

The SDP comprises two main components: one focused on Type 1 diabetes research and another dedicated to treatment and prevention strategies for American Indian and Alaska Native populations who face higher rates of Type 2 diabetes.

Currently, more than 37 million Americans are living with diabetes, which remains a leading cause of death nationwide. In addition to Senator Young, several other senators signed the letter advocating for continued support of the SDP.